Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.
Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H. Okura Y, et al. Among authors: akahane t. Hepatol Res. 2019 Feb;49(2):232-238. doi: 10.1111/hepr.13249. Epub 2018 Oct 9. Hepatol Res. 2019. PMID: 30198141
Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Mashitani T, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yamao J, Yoshiji H. Sawada Y, et al. Among authors: akahane t. Hepatol Res. 2019 Mar;49(3):284-295. doi: 10.1111/hepr.13281. Epub 2018 Dec 12. Hepatol Res. 2019. PMID: 30365236
Identification of clinical risk factors for histological progression of primary biliary cholangitis.
Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Takagi H, Noguchi R, Mitoro A, Yamao J, Yoshiji H. Fujinaga Y, et al. Among authors: akahane t. Hepatol Res. 2019 Sep;49(9):1015-1025. doi: 10.1111/hepr.13355. Epub 2019 Jun 14. Hepatol Res. 2019. PMID: 31021038
Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
Shimozato N, Namisaki T, Kaji K, Kitade M, Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, Sawada Y, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Asada K, Kitagawa K, Tsuji Y, Kaya D, Ozutsumi T, Akahane T, Mitoro A, Yoshiji H. Shimozato N, et al. Among authors: akahane t. Hepatol Res. 2019 Oct;49(10):1147-1161. doi: 10.1111/hepr.13385. Epub 2019 Jul 15. Hepatol Res. 2019. PMID: 31177586
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis.
Furukawa M, Moriya K, Nakayama J, Inoue T, Momoda R, Kawaratani H, Namisaki T, Sato S, Douhara A, Kaji K, Kitade M, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Tanaka Y, Yoshiji H. Furukawa M, et al. Among authors: akahane t. Hepatol Res. 2020 Jul;50(7):840-852. doi: 10.1111/hepr.13509. Epub 2020 Jun 10. Hepatol Res. 2020. PMID: 32346970
Role of serum albumin in hepatic encephalopathy.
Akahane T, Yoshiji H. Akahane T, et al. Hepatol Res. 2021 Apr;51(4):353-354. doi: 10.1111/hepr.13632. Hepatol Res. 2021. PMID: 33797845 No abstract available.
Evidence-based clinical practice guidelines for liver cirrhosis 2020.
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Yoshiji H, et al. Among authors: akahane t. Hepatol Res. 2021 Jul;51(7):725-749. doi: 10.1111/hepr.13678. Epub 2021 Jul 6. Hepatol Res. 2021. PMID: 34228859
Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis.
Enomoto M, Takaya H, Namisaki T, Fujinaga Y, Nishimura N, Sawada Y, Kaji K, Kawaratani H, Moriya K, Akahane T, Inoue T, Matsumoto M, Yoshiji H. Enomoto M, et al. Among authors: akahane t. Hepatol Res. 2022 Apr;52(4):390-400. doi: 10.1111/hepr.13743. Epub 2022 Jan 8. Hepatol Res. 2022. PMID: 34964539
312 results